BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 27083404)

  • 1. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity.
    Jorge ASB; Andrade JMO; Paraíso AF; Jorge GCB; Silveira CM; de Souza LR; Santos EP; Guimaraes ALS; Santos SHS; De-Paula AMB
    Obes Res Clin Pract; 2018; 12(Suppl 2):1-8. PubMed ID: 27083404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study.
    Ooi GJ; Burton PR; Bayliss J; Raajendiran A; Earnest A; Laurie C; Kemp WW; McLean CA; Roberts SK; Watt MJ; Brown WA
    Obes Surg; 2019 Jan; 29(1):99-108. PubMed ID: 30229460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease.
    du Plessis J; van Pelt J; Korf H; Mathieu C; van der Schueren B; Lannoo M; Oyen T; Topal B; Fetter G; Nayler S; van der Merwe T; Windmolders P; Van Gaal L; Verrijken A; Hubens G; Gericke M; Cassiman D; Francque S; Nevens F; van der Merwe S
    Gastroenterology; 2015 Sep; 149(3):635-48.e14. PubMed ID: 26028579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective case control study identifies peripheral blood mononuclear cell albumin RNA expression as a biomarker for non-alcoholic fatty liver disease.
    Chu X; Karasinski K; Donellan S; Kaniper S; Wood GC; Shi W; Edwards MA; Soans R; Still CD; Gerhard GS
    Langenbecks Arch Surg; 2020 Mar; 405(2):165-172. PubMed ID: 31828503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients.
    Paredes-Turrubiarte G; González-Chávez A; Pérez-Tamayo R; Salazar-Vázquez BY; Hernández VS; Garibay-Nieto N; Fragoso JM; Escobedo G
    Clin Exp Med; 2016 May; 16(2):193-202. PubMed ID: 25894568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of cell death mechanisms and fibrosis in visceral white adipose tissue with pathological alterations in the liver of morbidly obese patients with NAFLD.
    Leven AS; Gieseler RK; Schlattjan M; Schreiter T; Niedergethmann M; Baars T; Baba HA; Özçürümez MK; Sowa JP; Canbay A
    Adipocyte; 2021 Dec; 10(1):558-573. PubMed ID: 34743657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SFRP5 hepatic expression is associated with non-alcoholic liver disease in morbidly obese women.
    Gutiérrez-Vidal R; Vega-Badillo J; Reyes-Fermín LM; Hernández-Pérez HA; Sánchez-Muñoz F; López-Álvarez GS; Larrieta-Carrasco E; Fernández-Silva I; Méndez-Sánchez N; Tovar AR; Villamil-Ramírez H; Mejía-Domínguez AM; Villarreal-Molina T; Hernández-Pando R; Campos-Pérez F; Aguilar-Salinas CA; Canizales-Quinteros S
    Ann Hepatol; 2015; 14(5):666-74. PubMed ID: 26256895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic expression of Yin Yang 1 (YY1) is associated with the non-alcoholic fatty liver disease (NAFLD) progression in patients undergoing bariatric surgery.
    Yuan X; Chen J; Cheng Q; Zhao Y; Zhang P; Shao X; Bi Y; Shi X; Ding Y; Sun X; Xue B
    BMC Gastroenterol; 2018 Oct; 18(1):147. PubMed ID: 30285651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity depresses the anti-inflammatory HSP70 pathway, contributing to NAFLD progression.
    Di Naso FC; Porto RR; Fillmann HS; Maggioni L; Padoin AV; Ramos RJ; Mottin CC; Bittencourt A; Marroni NA; de Bittencourt PI
    Obesity (Silver Spring); 2015 Jan; 23(1):120-9. PubMed ID: 25292174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
    Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
    Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity.
    Walle P; Takkunen M; Männistö V; Vaittinen M; Lankinen M; Kärjä V; Käkelä P; Ågren J; Tiainen M; Schwab U; Kuusisto J; Laakso M; Pihlajamäki J
    Metabolism; 2016 May; 65(5):655-666. PubMed ID: 27085774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
    Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive Evaluation of NAFLD with Indocyanine Green Clearance Test: a Preliminary Study in Morbidly Obese Patients Undergoing Bariatric Surgery.
    Danin PE; Anty R; Patouraux S; Raucoules-Aimé M; Gugenheim J; Tran A; Gual P; Iannelli A
    Obes Surg; 2018 Mar; 28(3):735-742. PubMed ID: 28875438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CORRELATION BETWEEN NONALCOHOLIC FATTY LIVER DISEASE FEATURES AND LEVELS OF ADIPOKINES AND INFLAMMATORY CYTOKINES AMONG MORBIDLY OBESE INDIVIDUALS.
    Baltieri L; Chaim EA; Chaim FDM; Utrini MP; Gestic MA; Cazzo E
    Arq Gastroenterol; 2018; 55(3):247-251. PubMed ID: 30540086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
    Alqahtani A; Elahmedi M; Alswat K; Arafah M; Fagih M; Lee J
    Surg Obes Relat Dis; 2017 Sep; 13(9):1599-1609. PubMed ID: 28600116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.
    Lassailly G; Caiazzo R; Buob D; Pigeyre M; Verkindt H; Labreuche J; Raverdy V; Leteurtre E; Dharancy S; Louvet A; Romon M; Duhamel A; Pattou F; Mathurin P
    Gastroenterology; 2015 Aug; 149(2):379-88; quiz e15-6. PubMed ID: 25917783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity.
    Bedossa P; Tordjman J; Aron-Wisnewsky J; Poitou C; Oppert JM; Torcivia A; Bouillot JL; Paradis V; Ratziu V; Clément K
    Gut; 2017 Sep; 66(9):1688-1696. PubMed ID: 27884920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.